Whalesbook
India Considers Pharma Rule Deadline Extension Amidst Low Compliance
The Indian government is contemplating an extension for the implementation of revised Schedule M guidelines for pharmaceutical manufacturing, a move prompted by alarmingly low compliance rates among small and medium-sized enterprises (MSMEs). Sources indicate that with approximately 75% of pharma units yet to commence crucial upgradation work, a deadline extension might be unavoidable to prevent disruption.
The Core Issue
The primary challenge lies in the slow pace of compliance by MSMEs. Many of these smaller units face significant hurdles in undertaking the necessary upgrades to meet the enhanced manufacturing standards. These challenges range from practical implementation difficulties and a lack of clear understanding of specific regulatory provisions to the substantial financial investment required and the need for extensive personnel training.
Pharma Associates' Appeal to CDSCO
Industry bodies, including the Confederation of Indian Pharmaceutical Industry (CIPI), have formally requested the Central Drugs Standard Control Organisation (CDSCO) to extend the timeline for submitting upgradation plans. Specifically, they are seeking an extension until December 2026. This appeal stems from the interpretative uncertainties surrounding certain aspects of the revised guidelines, which have deterred some MSMEs from initiating their plans.
Jatish Sheth, secretary general of CIPI, highlighted the significant investment required, estimating costs to range between ₹2 crore and ₹10 crore, alongside recurring expenses to maintain the new production standards. He emphasized the industry's need for more time to adapt.
Financial Implications and Government Support
The revised Schedule M guidelines, notified in December 2023, represent a significant shift from focusing solely on 'good manufacturing practices' to encompassing detailed 'requirements of plan and equipment for pharmaceutical products'. This entails substantial upgrades in areas such as air quality, temperature control, sanitation, documentation, and raw material handling.
While the government has introduced measures like the revamped Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS), offering ₹300 crore for FY25-FY26 to support around 300 units, experts argue this support is insufficient. Spokespersons from pharma associations noted that the scheme covers less than 10% of the affected companies, leaving a considerable funding gap for MSMEs.
Market Reaction and Future Outlook
The potential extension could provide much-needed breathing room for MSMEs, allowing them to align with global quality standards without immediate financial strain. However, delaying implementation also raises concerns about India's reputation for drug quality and regulatory stringency in international markets. A prolonged delay could impact export competitiveness and investor confidence in the sector's long-term commitment to quality assurance. The government's decision will balance the immediate needs of smaller manufacturers with the imperative to uphold the highest standards of pharmaceutical production.
Impact Rating: 7/10
Difficult Terms Explained
- Schedule M: A set of rules and guidelines issued by the Central Drugs Standard Control Organisation (CDSCO) in India that specify the requirements for Good Manufacturing Practices (GMP) for pharmaceutical products.
- CDSCO: Central Drugs Standard Control Organisation. It is the national regulatory body responsible for the regulation of pharmaceuticals and medical devices in India.
- MSMEs: Micro, Small and Medium Enterprises. These are businesses classified based on their investment in plant and machinery and annual turnover, according to the MSMED Act.
- GMP: Good Manufacturing Practices. A system for ensuring that products are consistently produced and controlled according to quality standards.